FDA Grants Priority Review For Pfizer's NDA For Glasdegib - Quick Facts

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration or FDA accepted the company's New Drug Application and granted Priority Review designation for glasdegib.

from RTT - Biotech https://ift.tt/2Ks730C
via IFTTT